Revenue Increased 26% to $210.5 Million in 2020 Compared to Prior Year

Net Loss $(3.0) Million in Q4 2020 Versus Net Loss $(219.8) Million in Q4 2019

Achieved Adjusted EBITDA Goal With $2.2 Million in Q4 2020

Combination with Aphria Inc. Expected to Close in Q2 2021 to Create the World’s Largest Cannabis Company Based On Pro Forma Revenue

$189.7 Million Cash at December 31,2020 and $261.3 Million Cash as of February 16, 2021

Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today reported financial results for the full fiscal year and fourth quarter ended December 31, 2020. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Brendan Kennedy, Tilray’s Chief Executive Officer, stated, “Over the course of 2020, and despite COVID-19 related challenges, we transformed and strengthened Tilray, delivered solid full year results, significantly reduced net loss, and achieved our stated goal of delivering break even or positive Adjusted EBITDA in Q4 2020. We did so by generating meaningful revenue growth across our core businesses, particularly international medical and Canadian adult-use in Q4, and reducing costs by $57 million on an annualized basis compared to Q4 of 2019. As a result, we now operate with a more focused, efficient and competitive cost structure. We also strengthened our balance sheet and positioned Tilray for growth and success in the future in combination with Aphria. These results required hard work and dedication and I sincerely appreciate everything the Tilray team has done to transform our business during 2020. We now look forward to the beginning of the next chapter in our corporate journey.”

Mr. Kennedy continued, “Amid an acceleration of regulatory changes and an increasingly-favorable political environment, our proposed merger with Aphria will position the combined company as a global leader with lowest cost of production, leading brands, a well-developed distribution network, and unique partnerships. Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies. The aggregate impact of these value drivers provides confidence that the ‘new’ Tilray will generate significant value for stockholders.”

As announced on December 16, 2020, Tilray will combine businesses with Aphria Inc. and create the world’s largest global cannabis company based on pro forma revenue. Following the close of this transaction, which is expected in the second quarter of 2021, the combined company will operate under the Tilray corporate name with shares trading on Nasdaq under ticker symbol “TLRY”. Completion of the business combination is subject to regulatory and court approvals and other customary closing conditions, including the approval of Tilray and Aphria stockholders.

Fourth Quarter 2020 Financial Highlights

  • Total revenue increased to $56.6 (C$74.4) million, up 20.5% compared to the fourth quarter of 2019. Cannabis segment revenue increased 46% to $41.2 million (C$53.6 million), mainly driven by acceleration of International Medical sales (+191%) and Canadian Adult-Use sales (+49%). Canadian medical sales grew 26% and there were no bulk sales to other license producers. Hemp segment revenue decreased 18% to $15.3 million (C$20.5 million) primarily due to a shift to private label product with a large customer and the impact of COVID-related changes to consumer shopping patterns.
  • Total revenue increased 10% compared to the third quarter of 2020. Cannabis segment revenue increased 31%, driven by a 44% increase in International Medical sales, 27% increase in Adult-Use sales, and a 24% increase in Canada Medical sales which was partly offset by a 23% decline in Hemp sales.
TILRAY, INC. Revenue by Product (In thousands of United States dollars, except for percentage data)   Three months ended December 31, Twelve months ended December 31,

 

2020

 

2019

$ Change

% Change

 

2020

 

2019

$ Change

% Change

Cannabis Adult-use

$

25,362

$

17,005

$

8,357

 

49

%

$

83,828

$

55,763

$

28,065

 

50

%

Canada - medical

 

4,204

 

3,333

 

871

 

26

%

 

15,489

 

12,556

 

2,933

 

23

%

International - medical

 

11,666

 

4,008

 

7,658

 

191

%

 

33,886

 

13,378

 

20,508

 

153

%

Bulk

 

 

3,924

 

(3,924

)

(100

)%

 

402

 

25,450

 

(25,048

)

(98

)%

Total Cannabis revenue

$

41,232

$

28,270

$

12,962

 

46

%

$

133,605

$

107,147

$

26,458

 

25

%

Hemp

 

15,328

 

18,665

 

(3,337

)

(18

)%

 

76,877

 

59,832

 

17,045

 

28

%

Total

$

56,560

$

46,935

$

9,625

 

21

%

$

210,482

$

166,979

$

43,503

 

26

%

Excise duties included in revenue

$

5,818

$

4,429

$

1,389

 

31

%

$

19,143

$

13,136

$

6,007

 

46

%

  • Total cannabis kilogram equivalents sold decreased 54% to 6,901 kilograms from 15,039 kilograms in the prior year’s fourth quarter. The decrease was due almost entirely to the reduction of bulk sales.
  • Average cannabis net selling price per gram increased to $5.97(C$7.99) compared to $1.88 (C$2.52) in the fourth quarter of 2019 and decreased from $6.15 (C$8.15) in the third quarter of 2020. The increase versus 2019 was due to a continued shift in distribution channels and product mix, including growth in International Medical sales, a shift in sales to higher potency and higher priced products in the Adult-Use market, and the continued growth of Cannabis 2.0 products in Canada. The decrease from the third quarter of 2020 was due to the accelerated sales growth of cannabis flower products in the Canadian Adult-Use channel during the fourth quarter of 2020.
  • Average cannabis net cost per gram increased to $3.72 (C$4.98) compared to $1.53 (C$2.05) in the fourth quarter of 2019 and decreased from $4.23 (C$5.61) in the third quarter of 2020. The year-over-year increase was the result of lower kilograms sold due to the discontinuation of bulk sales and partly due to increased sales of Cannabis 2.0 products which have higher costs than dried flower. The decrease in the fourth quarter of 2020 is attributable to additional realization of cost cutting measures and better absorption rates in Portugal.
  • Gross margin increased to 29% from (121%)% in the fourth quarter of 2019 and increased from 7% in the third quarter of 2020.
  • Gross margin, excluding inventory valuation adjustments, increased to 33% from 23% in the fourth quarter of 2019 and 29% in the third quarter of 2020.
    • Gross margins for Cannabis, excluding inventory valuation adjustments, was 33% in the fourth quarter of 2020 versus 16% in the fourth quarter of 2019 and 27% in the third quarter of 2020. The sequential increase in gross margin was partly due to increased International Medical sales and lower costs at our production facilities resulting from our cost cutting measures.
    • Gross margin for Hemp, excluding inventory valuation adjustments, decreased to 34% from 35% in the fourth quarter of 2019 and decreased from 43% in the third quarter of 2020. The decreases are primarily due to a shift in sales to larger size and lower margin private label products with one of our large customers.
  • Net loss was $(3.0) million, or $(0.02) per share, compared to net loss of $(219.8) million, or $(2.14) per share, in the fourth quarter of 2019 and net loss of $(2.3) million, or $(0.02) per share in the third quarter of 2020.
  • Adjusted EBITDA of $2.2 million was a $37.5 million improvement compared to the $(35.3) million loss in the fourth quarter of 2019 and a $3.7 million improvement versus the $(1.5) million loss in the third quarter of 2020. Increased sales combined with our significant cost reductions and operating efficiencies had a meaningful positive impact on Adjusted EBITDA.
  • Cash and cash equivalents totaled $189.7 million at the end of the fourth quarter of 2020.

2020 Financial Highlights

  • Total revenue increased 26% to $210.5 (C$281.9) million during 2020 from $167.0 million in 2019. The increase was driven by $26.5 million or 25% growth in the Cannabis segment, and $17.0 million or 28% growth in the Hemp segment. The Hemp segment increase was partially due to the timing of the Manitoba Harvest acquisition in 2019 which resulted in 10 months of sales in 2019 compared to 12 months in 2020.
  • Total kilogram equivalents of cannabis sold decreased 17% during 2020 compared to 2019 generally due to a reduction in bulk sales which was partially offset by increases in other product channels. We expect continued increases in kilogram equivalents grams sold as we generate sales growth in our key cannabis product channels, Canadian Adult-Use and International Medical. Going forward, we will pursue opportunistic bulk sales as we manage our product mix and optimize margins.
  • The average net selling price per gram increased by 51% in 2020 to $4.57 (C$6.12) compared to $3.01 (C$3.99) in 2019 due to an increase in International Medical Sales and Cannabis 2.0 products accompanied by a reduction in Bulk sales. International medical markets sales generally command a higher price per gram than Adult-Use and Medical sales in Canada. The proportion of International Medical sales during the 2020 increased to 23% versus 12% in 2019. Additionally, higher-priced Cannabis 2.0 products, which did not exist in the comparable period in 2019, continued to grow as a percentage of our Adult-Use business.
  • The average cost per gram sold increased to $3.24 (C$4.34) representing a 37% increase during 2020 compared to $2.36 (C$3.12) in 2019 partially due to fewer kilograms sold as a result of reduced bulk sales, increased sales of Cannabis 2.0 products that have higher costs than dried flower, and partially due to limited absorption of costs at our facility in Portugal as we brought new growing capacity on line.
  • Gross margin increased to 12% from (14%) in 2019 primarily due to reduced inventory valuation adjustments and overall improvements in our cost of production related to our cost cutting efforts.
    • Gross margin for Cannabis, excluding inventory valuation adjustments, was 23% in 2020 and 20% in 2019. The improvement resulted from increased sales in International Medical markets, the introduction of 2.0 products in the Adult-Use market, and the realization of cost reduction measures implemented throughout the year.
    • Gross margin for Hemp of 37% in 2020 increased from 31% in 2019 due to reduced inventory adjustments. Gross margin for Hemp, excluding inventory valuation adjustments and purchase accounting value step-up, was 42% in 2020 and 43% in 2019. The decrease in gross margin was primarily due to a sales mix shift to larger and lower margin package sizes and lower absorption rates in our facilities towards the end of the year.
  • Net loss for the year decreased to $(271.1) million, or $(2.15) per share, compared to $(321.2) million or $(3.20) per share in 2019 largely due to the cost optimization measures undertaken during 2020. In 2020, we recorded non-cash impairment charges of $61.1 million and $38.4 million of inventory valuation adjustments, as well as a non-cash charge of $100.3 million related to warrant valuations, partially offset by non-cash gains on debt conversion of $(61.1) million. In 2019, we recorded non-cash charges of $112.1 million related to the impairment of the Authentic Brands Group LLC (“ABG”) agreement as well as $68.6 million in inventory valuation adjustments.
  • Adjusted EBITDA for the year improved to a loss of $(30.3) million compared to a loss of $(89.8) million in the prior year primarily due to cost reduction measures undertaken during 2020, and our ability to leverage sales growth with a reduced cost structure.

Recent Business Developments Reflect Strong, Ongoing Global Growth and Opportunity

Progress on Expanding International Medical Business and Canadian Adult-Use Product Line

  • On February 9, 2021, we announced a new agreement with Grow Pharma to import and distribute Tilray medical cannabis products in the United Kingdom. This new agreement gives doctors and patients access to a sustainable supply of Tilray’s full range of pharmaceutical-grade medical cannabis products.
  • On February 4, 2021, we announced our partnership with Worldpharma Biotech and our first export of medical cannabis from Portugal to Spain. Worldpharma will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis. Spain marks the 17th country where Tilray medical cannabis is available.
  • On February 1, 2021, we announced that we had received the necessary approvals and market authorization in accordance with the Portuguese legislation to offer Tilray medical cannabis products in Portugal from our GMP-certified EU facility in Cantanhede, Portugal. This is the first time a full quality dossier was required and delivered to obtain market authorization in Europe for a medical cannabis product.
  • On January 26, 2021, we announced that we have been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. We will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021.
  • On December 2, 2020, we announced that we had signed a cooperation agreement with Hormosan for the promotion of medical cannabis extracts in Germany. Hormosan is primarily focused on pain therapy and neurology and is part of the Lupin Group, an international entity that sells innovative drugs and generics. Through this strategic partnership, the expertise of both Tilray and Hormosan are now being leveraged to expand Tilray’s presence in the German market.
  • On October 5, 2020, our wholly-owned subsidiary, High Park Holdings Ltd., announced the newest addition to its cannabis-infused edible product line: Chowie Wowie Gummies. Chowie Wowie Gummies are handcrafted using clean and simple ingredients, are vegan and gluten free, and feature a delicious taste profile.

Progress on Strengthening Balance Sheet and Improving Financial Condition

  • Through February 15, 2021, warrant holders have exercised warrants to purchase approximately 12.7 million shares of Class 2 common stock at a price of $5.95 per share. The exercises resulted in proceeds of approximately $75.4 million and a reduction of our warrant liability of approximately $80.0 million.
  • On November 23 and 24, 2020, we announced that we had entered into privately negotiated exchange agreements with certain holders of its 5.00% Convertible Senior Notes due 2023 (the "Notes"). Pursuant to the exchange agreements, we exchanged approximately $197.2 million in aggregate principal amount of Notes plus accrued interest, for approximately 17.3 million shares of our Class 2 common stock. Following the exchange transactions, approximately $277.9 million in aggregate principal amount of the Notes remained outstanding. The purpose of the transaction was to reduce our debt and eliminate approximately $9.2 million in annual cash interest costs.

Conference Call

Tilray will host a conference call to discuss these results today at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-407-0792 from the U.S. and 201-689-8263 internationally.

There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will also be archived after the call concludes.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.

Forward Looking Statements

This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements regarding Aphria’s and Tilray’s strategic business combination and the expected terms, timing and closing of the combination, estimates of pro-forma financial information of the combined company, estimates of future cost reductions, synergies including pre-tax synergies, savings and efficiencies, value for stockholders, our growth potential, the sustainability of growth, the optimization of our facilities and estimated net savings, demand for our products and the medical and Adult-Use cannabis markets, anticipated plans for strategic partnerships and acquisitions, and future sales of our common stock. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

Use of Non-U.S. GAAP Financial Measures

To supplement its financial statements, the Company provides investors with information related to Adjusted EBITDA and gross margin, excluding inventory valuation adjustments, both of which are financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

Adjusted EBITDA is calculated as net income (loss) before inventory valuation adjustments; interest expenses, net; other expenses (income), net; deferred income tax (recoveries) expenses, current income tax expenses (benefit); foreign exchange gain (loss), net; depreciation and amortization expenses; stock-based compensation expenses; loss from equity method investments; finance income from ABG; loss on disposal of property and equipment; amortization of inventory step-up; severance costs; impairment of assets; and change in fair value of warrant liability. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Gross margin, excluding inventory valuation adjustments and stock-based compensation, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, and stock-based compensation divided by revenue. A reconciliation of Gross margin, excluding inventory valuation adjustments and stock-based compensation, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

The Company believes these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. Management uses these non-GAAP financial measures to compare the Company's performance to that of prior periods for trend analyses and planning purposes. These non-GAAP financial measures are also presented to the Company’s Board of Directors.

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Non-U.S. GAAP measures exclude significant expenses that are required by U.S. GAAP to be recorded in the Company's financial statements and are subject to inherent limitations.

Additional Information About the Tilray and Aphria Business Combination and Where to Find It

This news release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This statements in this press release in respect of the proposed transaction involving Aphria and Tilray pursuant to the terms of an arrangement agreement by and among Aphria and Tilray may be deemed to be soliciting material relating to the proposed transaction.

In connection with the proposed transaction, Aphria will file a management information circular, and Tilray will file a proxy statement on Schedule 14A containing important information about the proposed transaction and related matters. Additionally, Aphria and Tilray will file other relevant materials in connection with the proposed transaction with the applicable securities regulatory authorities. Investors and security holders of Aphria and Tilray are urged to carefully read the entire management information circular and proxy statement (including any amendments or supplements to such documents), respectively, when such documents become available before making any voting decision with respect to the proposed transaction because they will contain important information about the proposed transaction and the parties to the transaction. The Aphria management information circular and the Tilray proxy statement will be mailed to the Aphria and Tilray shareholders, respectively, as well as be accessible on the SEDAR and EDGAR profiles of the respective companies.

Investors and security holders of Tilray will be able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about Tilray and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the SEC’s website (www.sec.gov) or from Tilray by contacting Tilray’s Investor Relations at (203) 682-8253, by email at Raphael.Gross@icrinc.com, or by going to Tilray’s Investor Relations page on its website at https://ir.tilray.com/investor-relations and clicking on the link titled “Financials.”

Participants in the Tilray Solicitation

Tilray and Aphria and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of Tilray proxies in respect of the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Tilray stockholders in connection with the proposed transaction will be set forth in the Tilray proxy statement for the proposed transaction when available. Other information regarding the participants in the Tilray proxy solicitation and a description of their direct and indirect interests in the proposed transaction, by security holdings or otherwise, will be contained in such proxy statement and other relevant materials to be filed with the SEC in connection with the proposed transaction. Copies of these documents may be obtained, free of charge, from the SEC or Tilray as described in the preceding paragraph.

  TILRAY, INC. Consolidated Statements of Net Loss and Comprehensive Loss (In thousands of United States dollars, except for share and per share data)   Three months endedDecember 31, Year endedDecember 31,

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

$

56,560

 

$

46,936

 

$

210,482

 

$

166,979

 

Cost of sales

 

39,918

 

 

103,943

 

 

185,827

 

 

190,475

 

Gross profit

 

16,642

 

 

(57,007

)

 

24,655

 

 

(23,496

)

General and administrative expenses

 

22,597

 

 

42,836

 

 

85,883

 

 

110,903

 

Sales and marketing expenses

 

6,638

 

 

22,741

 

 

54,666

 

 

63,813

 

Research and development expenses

 

928

 

 

2,450

 

 

4,411

 

 

9,172

 

Depreciation and amortization expenses

 

3,369

 

 

4,150

 

 

13,722

 

 

11,607

 

Impairment of assets

 

2,904

 

 

112,070

 

 

61,114

 

 

112,070

 

Acquisition-related expenses (income), net

 

 

 

(24,861

)

 

 

 

(31,427

)

Loss from equity method investments

 

1,488

 

 

2,667

 

 

5,983

 

 

4,504

 

Operating loss

 

(21,282

)

 

(219,060

)

 

(201,124

)

 

(304,138

)

Foreign exchange (gain) loss, net

 

(18,593

)

 

(7,097

)

 

(13,169

)

 

(5,944

)

Change in fair value of warrant liability

 

49,011

 

 

 

 

100,286

 

 

 

Gain on debt conversion

 

(61,118

)

 

 

 

(61,118

)

 

 

Interest expenses, net

 

9,072

 

 

8,685

 

 

39,219

 

 

34,690

 

Finance income from ABG

 

 

 

(207

)

 

 

 

(764

)

Other expense (income), net

 

5,387

 

 

3,572

 

 

10,333

 

 

(2,501

)

Loss before income taxes

 

(5,041

)

 

(224,013

)

 

(276,675

)

 

(329,619

)

Deferred income tax (recoveries)

 

(1,363

)

 

(4,860

)

 

(5,376

)

 

(8,847

)

Current income tax (recoveries) expenses

 

(731

)

 

(5

)

 

(226

)

 

397

 

Net loss

$

(2,947

)

$

(219,148

)

$

(271,073

)

$

(321,169

)

Net loss per share - basic and diluted

$

(0.02

)

$

(2.14

)

$

(2.15

)

$

(3.20

)

Weighted average shares used in computation of net loss per share - basis and diluted

 

143,819,967

 

 

102,405,607

 

 

126,041,710

 

 

100,455,677

 

Net loss

 

(2,947

)

 

(219,148

)

 

(271,073

)

 

(321,169

)

Foreign currency translation (loss) gain, net

 

5,687

 

 

7,588

 

 

(1,497

)

 

5,174

 

Unrealised loss on investments

 

(171

)

 

(101

)

 

(17

)

 

(21

)

Other comprehensive income (loss)

 

5,516

 

 

7,487

 

 

(1,514

)

 

5,153

 

Comprehensive income (loss)

$

2,569

 

$

(211,661

)

$

(272,587

)

$

316,016

 

 

As stated in our Form-10K, share-based compensation expenses have been reclassified to their respective functional lines in the Consolidated Statements of Net Loss and Comprehensive loss. This was adjusted retrospectively for 2018, 2019 and 2020 and applied in the fourth quarter of 2020.

  TILRAY, INC. Consolidated Balance Sheets (In thousands of United States dollars, except for share and par value data)   December 31,2020 December 31,2019 Assets Current assets: Cash and cash equivalents

$

189,702

 

$

96,791

 

Accounts receivable, net of allowance for credit losses of $887 and provision for sales returns of $1,651 (December 31, 2019 - $615 and $1,400, respectively)

 

29,033

 

 

36,202

 

Inventory

 

93,645

 

 

87,861

 

Prepayments and other current assets

 

34,640

 

 

38,173

 

Total current assets

 

347,020

 

 

259,027

 

Property and equipment, net

 

199,559

 

 

184,217

 

Operating lease, right-of-use assets

 

17,985

 

 

17,514

 

Intangible assets, net

 

186,445

 

 

228,828

 

Goodwill

 

166,915

 

 

163,251

 

Equity method investments

 

9,300

 

 

11,448

 

Other investments

 

14,369

 

 

24,184

 

Other assets

 

4,356

 

 

7,861

 

Total assets

$

945,949

 

$

896,330

 

Liabilities Current liabilities Accounts payable

 

17,776

 

 

39,125

 

Accrued expenses and other current liabilities

 

39,946

 

 

50,829

 

Accrued lease obligations

 

2,913

 

 

2,473

 

Warrant liability

 

120,647

 

 

 

Total current liabilities

 

181,282

 

 

92,427

 

Accrued lease obligations

 

30,623

 

 

29,407

 

Deferred tax liability

 

49,274

 

 

53,363

 

Convertible notes, net of issuance costs

 

257,789

 

 

430,210

 

Senior Facility, net of transaction costs

 

48,470

 

 

 

Other liabilities

 

4,612

 

 

5,652

 

Total liabilities

$

572,050

 

$

611,059

 

  Commitments and contingencies

 

 

 

 

  Stockholders’ equity Convertible Preferred stock ($0.0001 par value, 10,000,000 sharesauthorized and none issued or outstanding at December 31, 2018;none authorized, issued or outstanding at December 31, 2017)

 

 

 

 

Class 1 common stock ($0.0001 par value, 233,333,333 and 250,000,000 shares authorized;0 and 16,666,667 shares issued and outstanding)

 

 

 

2

 

Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized;158,456,087 and 86,114,558 shares issued and outstanding, respectively)

 

16

 

 

9

 

Class 3 common stock ($0.0001 par value, none authorized, issued oroutstanding at December 31, 2018; none authorized, issued or outstanding at December 31, 2017) Additional paid-in capital

 

1,095,781

 

 

705,671

 

Accumulated other comprehensive income

 

8,205

 

 

9,719

 

Accumulated deficit

 

(730,103

)

 

(430,130

)

Total stockholders' equity

$

373,899

 

$

285,271

 

Total liabilities and stockholders' equity

$

945,949

 

$

896,330

 

TILRAY, INC. Adjusted EBITDA (In thousands of United States dollars)   Three months endedDecember 31, Year endedDecember 31,

2020

 

2019

 

2020

 

2019

 

Adjusted EBITDA reconciliation: Net loss $

(2,949

)

$

(219,148

)

$

(271,073

)

$

(321,169

)

Inventory valuation adjustments

2,303

 

67,857

 

38,419

 

68,583

 

Severance costs

1,288

 

 

4,864

 

 

Depreciation and amortization expenses

4,422

 

5,389

 

18,654

 

15,849

 

Stock-based compensation expenses

6,312

 

9,539

 

29,716

 

31,842

 

Other stock-based compensation related expenses

 

8,411

 

 

8,411

 

Gain on debt conversion

(61,118

)

 

(61,118

)

 

Impairment of assets

2,904

 

112,070

 

61,114

 

112,070

 

Loss from equity method investments

1,488

 

2,667

 

5,983

 

4,504

 

Foreign exchange (gain) loss, net

(18,593

)

(7,097

)

(13,169

)

(5,944

)

Change in fair value of warrant liability

49,011

 

 

100,286

 

 

Interest expenses, net

9,072

 

8,685

 

39,219

 

34,690

 

Finance income from ABG

 

(207

)

 

(764

)

Loss from disposal of property and equipment

958

 

2,324

 

1,851

 

2,436

 

Other expenses (income), net

9,244

 

(21,177

)

20,573

 

(33,928

)

Amortization of inventory step-up

 

 

 

2,041

 

Deferred income tax recoveries

(1,363

)

(4,860

)

(5,376

)

(8,847

)

Current income tax (recoveries) expenses

(731

)

(5

)

(226

)

397

 

Adjusted EBITDA $

2,248

 

$

(35,552

)

$

(30,283

)

$

(89,829

)

    TILRAY, INC. Gross Margin (In thousands of United States dollars, except for percentage data)   For the three months ended December 31, Cannabis Hemp Total

 

2020

 

 

2019

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

$

41,232

 

$

28,270

 

$

15,328

 

$

18,665

 

$

56,560

 

$

46,935

 

Cost of sales Product costs

 

26,152

 

 

23,864

 

 

9,900

 

 

12,221

 

 

36,052

 

 

36,085

 

Inventory valuation adjustments

 

2,753

 

 

62,922

 

 

(450

)

 

4,935

 

 

2,303

 

 

67,857

 

Stock-based compensation expenses

 

1,292

 

 

 

 

271

 

 

 

 

1,563

 

 

 

Gross profit (loss)

 

11,035

 

 

(58,516

)

 

5,607

 

 

1,509

 

 

16,642

 

 

(57,007

)

Inventory valuation adjustments

 

2,753

 

 

62,922

 

 

(450

)

 

4,935

 

 

2,303

 

 

67,857

 

Stock-based compensation expenses

1,292

271

1,563

  Gross profit, excluding inventory valuation adjustments and stock-based compensation expenses

$

15,080

 

$

4,406

 

$

5,428

 

$

6,444

 

$

20,508

 

$

10,850

 

Gross margin, excluding inventory valuation adjustments and stock-based compensation expenses

 

37

%

 

16

%

 

35

%

 

35

%

 

36

%

 

23

%

  For the year ended December 31, Cannabis Hemp Total

 

2020

 

 

2019

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

$

133,605

 

$

107,147

 

$

76,877

 

$

59,832

 

$

210,482

 

$

166,979

 

Cost of sales Product costs

 

101,509

 

 

84,876

 

 

44,336

 

 

35,395

 

$

145,845

 

$

120,271

 

Inventory valuation adjustments

 

34,379

 

 

63,532

 

 

4,040

 

 

5,050

 

$

38,419

 

$

68,582

 

Stock-based compensation expenses

 

1,292

 

 

1,041

 

 

271

 

 

581

 

 

1,563

 

 

1,622

 

Gross profit (loss)

 

(3,575

)

 

(42,302

)

 

28,230

 

 

18,806

 

$

24,655

 

$

(23,496

)

Inventory valuation adjustments

 

34,379

 

 

63,532

 

 

4,040

 

 

5,050

 

$

38,419

 

$

68,582

 

Amortization of inventory step-up

 

 

 

 

 

 

 

2,041

 

$

 

$

2,041

 

Stock-based compensation expenses

 

1,292

 

 

1,041

 

 

271

 

 

581

 

$

1,563

 

$

1,622

 

Gross profit, excluding inventory valuation adjustments and stock-based compensation expenses

$

32,096

 

$

22,271

 

$

32,541

 

$

26,478

 

$

64,637

 

$

48,749

 

Gross margin, excluding inventory valuation adjustments and stock-based compensation expenses

 

23

%

 

20

%

 

42

%

 

43

%

 

30

%

 

28

%

 

Media: Berrin Noorata, news@tilray.com Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com